/ Active, not recruiting临床4期IIT An Open Label, Comparative, Randomized , Phase IV Pilot Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
In HIV-infected people with metabolic fatty liver disease and liver fibrosis of any degree, as measured by non-invasive testing, antiretroviral treatment that includes rilpivinire for 18 months results in a slowing of progression and/or reduction of fatty metabolic liver disease, attenuating inflammation and liver fibrosis.
/ Active, not recruiting临床4期IIT Phase IV, Randomized, Multicenter and Double Clinical Trial Blind Designed to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities: MIND Study
In people infected with HIV, with suppressed HIV viral load and receiving treatment with DTG/3TC:
The change to BIC/FTC/TAF will decrease the development of adverse events of neuropsychiatric etiology.
The change to BIC/FTC/TAF may improve the patient´s tolerability and degree of acceptance and use of TAR.
Simplified Model of Linkage and Retention to Healthcare System, Using a Mobil Unit and a Same-day Test and Treat Approach Among Excluded Population.
Implementation of a model for access and retention of HIV care for vulnerable and excluded population using a mobile screening unit and a strategy of diagnosis and initiation of treatment with Bictegravir (BIC) 50 mg/ Emtricitabine (FTC) 200 mg / Tenofovir Alafenamide (TAF) 25 mg.
100 项与 SEIMC-GESIDA Foundation 相关的临床结果
0 项与 SEIMC-GESIDA Foundation 相关的专利（医药）
100 项与 SEIMC-GESIDA Foundation 相关的药物交易
100 项与 SEIMC-GESIDA Foundation 相关的转化医学
